Nexell launches cell selection system in Europe:
This article was originally published in Clinica
Executive Summary
Nexell Therapeutics, a subsidiary of Vimrx Pharmaceuticals has launched its second-generation Isolex 300k cell selection system in Europe. The Irvine, California-based system is the first such product with fully automated DC34+ cell selection and breast cancer cell purging capability to have received the CE mark. The new system has an improved disposable set design which is intended to improve CD34+ cell selection performance. Last month, Nexell received an approvable letter from the US FDA for the first-generation Isolex 300I system for positive selection of CD34+ cells.